Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Insider Sells $45,560.32 in Stock

Jazz Pharmaceuticals plc (NASDAQ:JAZZGet Rating) insider Neena M. Patil sold 296 shares of the firm’s stock in a transaction dated Friday, May 6th. The shares were sold at an average price of $153.92, for a total value of $45,560.32. Following the completion of the transaction, the insider now directly owns 32,677 shares in the company, valued at $5,029,643.84. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of Jazz Pharmaceuticals stock opened at $144.03 on Wednesday. The business has a 50-day moving average price of $158.89 and a 200 day moving average price of $142.69. Jazz Pharmaceuticals plc has a fifty-two week low of $117.64 and a fifty-two week high of $189.00. The firm has a market cap of $8.98 billion, a P/E ratio of -19.18, a P/E/G ratio of 1.31 and a beta of 0.79. The company has a quick ratio of 1.90, a current ratio of 3.39 and a debt-to-equity ratio of 1.66.

Jazz Pharmaceuticals (NASDAQ:JAZZGet Rating) last posted its quarterly earnings results on Wednesday, May 4th. The specialty pharmaceutical company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.00 by $0.73. The business had revenue of $813.72 million for the quarter, compared to analyst estimates of $853.73 million. Jazz Pharmaceuticals had a positive return on equity of 22.45% and a negative net margin of 13.63%. The business’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the company posted $3.42 EPS. As a group, equities research analysts anticipate that Jazz Pharmaceuticals plc will post 13.55 earnings per share for the current year.

Several equities research analysts recently commented on the company. The Goldman Sachs Group downgraded Jazz Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $202.00 to $196.00 in a report on Wednesday, April 6th. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, April 26th. Needham & Company LLC reaffirmed a “buy” rating and set a $215.00 price target on shares of Jazz Pharmaceuticals in a research note on Monday, February 7th. Cowen boosted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $225.00 in a report on Thursday, May 5th. Finally, HC Wainwright raised their target price on Jazz Pharmaceuticals from $210.00 to $215.00 and gave the company a “buy” rating in a research note on Thursday, March 3rd. Three investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat.com, Jazz Pharmaceuticals has an average rating of “Buy” and a consensus price target of $206.47.

Several large investors have recently made changes to their positions in the stock. Private Capital Group LLC lifted its holdings in Jazz Pharmaceuticals by 1,975.0% in the first quarter. Private Capital Group LLC now owns 166 shares of the specialty pharmaceutical company’s stock worth $26,000 after acquiring an additional 158 shares during the last quarter. Lloyd Advisory Services LLC. bought a new position in Jazz Pharmaceuticals during the 1st quarter worth $29,000. Quent Capital LLC acquired a new stake in Jazz Pharmaceuticals in the fourth quarter worth $31,000. National Bank of Canada FI bought a new stake in Jazz Pharmaceuticals in the fourth quarter valued at $35,000. Finally, C M Bidwell & Associates Ltd. acquired a new position in shares of Jazz Pharmaceuticals during the first quarter valued at $45,000. 93.23% of the stock is owned by institutional investors and hedge funds.

About Jazz Pharmaceuticals (Get Rating)

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors.

Recommended Stories

Insider Buying and Selling by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.